Skip to Content

Vimpat Approval History

  • FDA approved: Yes (First approved October 28th, 2008)
  • Brand name: Vimpat
  • Generic name: lacosamide
  • Dosage form: Tablets and Injection
  • Company: UCB
  • Treatment for: Seizures

Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Development History and FDA Approval Process for Vimpat

Oct 29, 2008Approval UCB's Vimpat Approved By U.S. FDA As Adjunctive Therapy for Partial Onset Seizures in Adults
Jul 29, 2008UCB Receives Not-Approvable Letter from FDA for Lacosamide for Diabetic Neuropathic Pain
Nov 29, 2007UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
Nov 28, 2007UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.